- Brick-by-brick, India is restoring clinical trials 'parity'
- 5 burning questions for India's crisis-hit clinical research community
- Is the Indian clinical trials segment pick up a mirage?
- Experts slam crippling Indian trial regulations
ANALYSIS Other Informa Analysis
COMMENT Other Informa Comment
- Profile: Novartis India boss on a working mother, karma & his wrist watch
- The EMA at 20: Guido Rasi looks at how the EU regulatory landscape might change over the next decade